BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NVPRNewsWire • 05/08/24
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual MeetingPRNewsWire • 05/04/24
Gear Up for BioMarin (BMRN) Q1 Earnings: Wall Street Estimates for Key MetricsZacks Investment Research • 04/22/24
BioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 04/17/24
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ETPRNewsWire • 04/10/24
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics MeetingPRNewsWire • 03/12/24
Here's What Key Metrics Tell Us About BioMarin (BMRN) Q4 EarningsZacks Investment Research • 02/23/24
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024PRNewsWire • 02/22/24
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & MoreZacks Investment Research • 02/21/24